Hatteras — 2016 Investments
1 investments dated 2016 · listed companies and verified rows first · show all
Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology.
BiotechHealthtechMedical DevicesAlpharetta, US
Mark Prausnitz(Director)inCharles Deignan(Executive Officer)Glenn Noronha(Executive Officer)inDaniel H. White(Executive Officer, Director)in
BoardEvgeny Zaytsev(Director)Derek Yoon(Director)in
Board seatClay B. Thorp· per SEC Form D · $320K raise · filed Oct 2016
Co-investorsHEALTHCARE ROYALTY PARTNERSMountain Group CapitalSolasta VenturesHatteras Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.